{"id":16044,"date":"2022-03-28T20:23:48","date_gmt":"2022-03-28T18:23:48","guid":{"rendered":"https:\/\/convergences.online\/hemato\/?p=16044"},"modified":"2024-12-11T15:09:44","modified_gmt":"2024-12-11T14:09:44","slug":"bitherapie-dans-la-myelofibrose","status":"publish","type":"post","link":"https:\/\/www.hematostat.net\/en\/bitherapie-dans-la-myelofibrose\/","title":{"rendered":"Bith\u00e9rapie dans la my\u00e9lofibrose"},"content":{"rendered":"<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:1302px;margin-left: calc(-5% \/ 2 );margin-right: calc(-5% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:2.375%;--awb-margin-bottom-large:0px;--awb-spacing-left-large:2.375%;--awb-width-medium:100%;--awb-spacing-right-medium:2.375%;--awb-spacing-left-medium:2.375%;--awb-width-small:100%;--awb-spacing-right-small:2.375%;--awb-spacing-left-small:2.375%;\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-text fusion-text-1\"><p>R\u00e9f. : HematoStat.net ; 3 (1) : R50<\/p>\n<div><i>Harrison CN, Garcia JS, Somervaille TCP, Foran JM, Verstovsek S, Jamieson C, et al. <span lang=\"EN-US\">Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy. <\/span>J Clin Oncol. 18 f\u00e9vr 2022;JCO.21.02188.<\/i><\/div>\n<div><\/div>\n<h3>R\u00e9sum\u00e9<\/h3>\n<div><\/div>\n<div>Le navitoclax (inhibiteur de Bcl-2, Bcl-xL et Bcl-w) est, dans cet essai de phase 2, ajout\u00e9 au ruxolitinib chez des patients atteints de my\u00e9lofibrose (MF) non r\u00e9pondeurs ou en progression. \u00c0 24 semaines, 9 patients sur 34 pr\u00e9sentaient une r\u00e9duction \u2265 35 % de leur spl\u00e9nom\u00e9galie (dur\u00e9e m\u00e9diane de r\u00e9ponse : 13,8 mois) et 6 patients sur 20 constataient une am\u00e9lioration nette de leurs signes g\u00e9n\u00e9raux (TSS<sub>50<\/sub>). Effet secondaire principal : la thrombop\u00e9nie.<\/div>\n<div><\/div>\n<h3>Dans nos pratiques<\/h3>\n<div><\/div>\n<div>Les patients atteints de MF non \u00e9ligibles \u00e0 une allogreffe et r\u00e9sistants ou intol\u00e9rant au ruxolitinb disposent actuellement de tr\u00e8s peu d\u2019options th\u00e9rapeutiques. Signal int\u00e9ressant pour le navitoclax qui semble permettre de d\u00e9passer, chez certains patients, la r\u00e9sistance au ruxolitinib utilis\u00e9 en monoth\u00e9rapie. Devant ces bons r\u00e9sultats, une \u00e9tude de phase 3 \u00e9valuant le ruxolitinib en association au navitoclax en premi\u00e8re ligne est en cours.<\/div>\n<div><\/div>\n<h3>Critique m\u00e9thodologique<\/h3>\n<div><\/div>\n<div>Cet essai de phase 2 a pour objectif principal la r\u00e9duction de la spl\u00e9nom\u00e9galie qui est tr\u00e8s bon crit\u00e8re clinique et facilement \u00e9valuable. Le nombre peu \u00e9lev\u00e9 de patient permet de disposer de l\u2019\u00e9volution de la rate et des sympt\u00f4mes notamment patient par patient sous forme graphique. Utile aussi l\u2019\u00e9volution au cours du temps du taux plaquettaire.<\/div>\n<\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":16,"featured_media":15574,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[36],"tags":[],"ppma_author":[456],"class_list":["post-16044","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-revue-de-presse","author-alexis-genthon"],"aioseo_notices":[],"authors":[{"term_id":456,"user_id":16,"is_guest":0,"slug":"alexis-genthon","display_name":"Alexis GENTHON","avatar_url":{"url":"https:\/\/www.hematostat.net\/wp-content\/uploads\/2023\/06\/Capture-decran-2021-05-07-a-14.25.02.png","url2x":"https:\/\/www.hematostat.net\/wp-content\/uploads\/2023\/06\/Capture-decran-2021-05-07-a-14.25.02.png"},"first_name":"","last_name":"","user_url":"","description":"H\u00e9matologue.\r\nCorrespondance : H\u00f4pital Saint-Antoine \r\nService h\u00e9matologie clinique\r\n184 rue du Faubourg Saint-Antoine 75012 Paris."}],"_links":{"self":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/16044","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/comments?post=16044"}],"version-history":[{"count":1,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/16044\/revisions"}],"predecessor-version":[{"id":18220,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/16044\/revisions\/18220"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/"}],"wp:attachment":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/media?parent=16044"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/categories?post=16044"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/tags?post=16044"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/ppma_author?post=16044"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}